Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer’s Disease

Title:Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer’s Disease

Volume: 17 Issue: 9

Author(s): Patrycja Michalska, Izaskun Buendia, Laura del Barrio and Rafael Leon

Affiliation:

Keywords: Alzheimer's disease, Hybrid compounds, Drug design, Multitarget drugs, Emerging targets for AD, Dual AChE Inhibitors, Antioxidants, Nrf2-EpRE inducers.

Abstract: Alzheimer’s disease (AD) is the most prevalent among the aging diseases known as neurodegenerative disorders. Drug design programs over the last two decades were mainly based on the cholinergic, the amyloid or the tau hypothesis. However, none of the new drugs have a real impact on the outcome of the disease. The complex nature of AD has led to new approaches for drug development programs, the multitarget drug design hypothesis. Based on this hypothesis, the generation of multitarget hybrid compounds from previously known active molecules has been one of the most widely used to obtain new candidates for the future treatment of AD. Here, we summarize recent developments based on the hybridization hypothesis to obtain a potential clinical candidate for AD.

Cite this article as:

Michalska Patrycja, Buendia Izaskun, Barrio del Laura and Leon Rafael, Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer’s Disease, Current Topics in Medicinal Chemistry 2017; 17 (9) . https://dx.doi.org/10.2174/1568026616666160927154116